Literature DB >> 11324928

Osteogenesis imperfecta: lifelong management is imperative and feasible.

G Chevrel1, P J Meunier.   

Abstract

Osteogenesis imperfecta is a group of inherited diseases responsible for varying degrees of skeletal fragility. Minimal trauma is sufficient to cause fractures and bone deformities. The classification of osteogenesis imperfecta has recently been improved by the inclusion of additional clinical and histomorphometric data. The diagnosis is often readily made in infancy; some cases, however, go unrecognized until adulthood. Lifelong multidisciplinary management is imperative. Pamidronate therapy in childhood is the most extensively studied treatment and has been proved beneficial. Other bisphosphonates are being evaluated, particularly in adults. Prevention of vitamin D and calcium deficiency is essential throughout life. Pain is common and should be given adequate attention.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11324928     DOI: 10.1016/s1297-319x(01)00256-1

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  4 in total

1.  Impact of fracture characteristics and disease-specific complications on health-related quality of life in osteogenesis imperfecta.

Authors:  Masaki Matsushita; Kenichi Mishima; Satoshi Yamashita; Nobuhiko Haga; Sayaka Fujiwara; Keiichi Ozono; Takuo Kubota; Taichi Kitaoka; Naoki Ishiguro; Hiroshi Kitoh
Journal:  J Bone Miner Metab       Date:  2019-08-13       Impact factor: 2.626

2.  Characterization of skin abnormalities in a mouse model of osteogenesis imperfecta using high resolution magnetic resonance imaging and Fourier transform infrared imaging spectroscopy.

Authors:  H C Canuto; K W Fishbein; A Huang; S B Doty; R A Herbert; J Peckham; N Pleshko; R G Spencer
Journal:  NMR Biomed       Date:  2011-08-15       Impact factor: 4.044

3.  Conservative versus surgical treatment of osteogenesis imperfecta: a retrospective analysis of 29 patients.

Authors:  Eugenio Chiarello; Davide Donati; Giuseppe Tedesco; Luca Cevolani; Tommaso Frisoni; Matteo Cadossi; Martha Hoque; Benedetta Spazzoli; Sandro Giannini
Journal:  Clin Cases Miner Bone Metab       Date:  2012-12-20

4.  Bisphosphonate treatment in the oim mouse model alters bone modeling during growth.

Authors:  S H Rao; K D Evans; A M Oberbauer; R B Martin
Journal:  J Biomech       Date:  2008-11-20       Impact factor: 2.712

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.